Navigation Links
Millennium Expands IBD Franchise with Addition of New Development Candidate
Date:3/17/2008

- Company advances oral antagonist of CCR9, a chemokine receptor believed

to play a critical role in Crohn's disease -

CAMBRIDGE, Mass., March 17 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the advancement of MLN3126, a new product candidate, from the Company's discovery engine to its development pipeline. MLN3126 is a selective antagonist of CCR9, a chemokine receptor known to be important in the migration of inflammatory cells into the gastrointestinal tract. Along with MLN0002, an antibody targeting the alpha4beta7 integrin, MLN3126 expands the Company's inflammatory bowel disease (IBD) franchise. MLN0002 already has demonstrated the ability to induce clinical remission in patients with ulcerative colitis and Crohn's disease and is expected to enter pivotal Phase III trials in late 2008 or early 2009 in both indications.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The development of MLN3126 leverages our knowledge and experience in the area of IBD, a key focus area for Millennium," said Deborah Dunsire, M.D., Chief Executive Officer, Millennium. "Building on our scientific knowledge and broad patent estate in the area of chemokines, we have identified a product candidate that is differentiated from others in this field and potentially could benefit the millions of patients afflicted with Crohn's worldwide."

"We are delighted to move forward some very promising molecules in IBD. In addition to the positive direction of MLN3126, preliminary results from bridging studies with MLN0002 from our new commercially scalable cell line show favorable pharmaco
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation
2. Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation
3. 2008 Susquehanna Healthcare Conference to Webcast Millennium Presentation
4. BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation
5. 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference to Webcast Millennium Presentation
6. Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology
7. Millennium Enters Into $600,000 Product Development Agreement to Fund Product Development for the $20,000,000 Purchase Agreement with Provider Services, Inc.
8. Millennium to Webcast Business Update in Advance of 26th Annual JPMorgan Healthcare Conference
9. Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
10. Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event
11. Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
(Date:9/19/2014)... 9/18/14) A leading Dartmouth researcher, working with The Melanoma ... paper published today in the Journal of the ... the risk of melanoma. , "For the first time, ... of these telomeres play a part in the risk ... Mark Iles, PhD, School of Medicine at the University ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Melanoma risk found to have genetic determinant 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... 6 Cowen Group, Inc. (Nasdaq: COWN ) ... a Senior Analyst covering managed care and health care service ... covered health care services stocks from 1999 to 2008. ... the lead analyst covering healthcare services. Between 2000 and ...
... 6 Prism Pharmaceuticals, Inc.,announced today that Dr. Warren ... the 27th Annual J.P. Morgan Healthcare Conference on,Tuesday, January ... a.m. (Eastern,Time). The conference will be held at ... Dr. Cooper will present corporate ...
... SMTS ) will release its financial results for ... before the opening of the market on,Wednesday, January 21, ... will host a conference call that will be webcast ... On the conference call, Bruce Barrett, ...
... at Home Depot saw big increase in employees working out ... to work out works, a new study says. , ... to support workers in setting exercise goals notably increased their ... The findings were published in the February edition of ...
... Design Creates Tangible Value by Revealing New Revenue ... LLC, a firm that specializes in designing customer-centric ... for growth-oriented companies, today announced its official launch. ... build and launch new services around business opportunities ...
... Population is Undertreated When Compared to California, According ... Mass., Jan. 6 Decision Resources, one of ... on pharmaceutical and healthcare issues, finds that Florida ... the Alzheimer,s disease drug market despite the large ...
Cached Medicine News:Health News:Cowen Adds Health Care Service Analyst to Equity Research Department 2Health News:Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009 2Health News:Employer-Sponsored Workouts Boost Workers' Health 2Health News:First Service Design Firm Launches in United States 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 3
(Date:9/19/2014)... Sept. 19, 2014  The board of directors of ... quarterly cash dividend of $0.42 per share.  ... to stockholders of record at the close of business ... is a global, research-based biopharmaceutical company formed in 2013 ... use its expertise, dedicated people and unique approach to ...
(Date:9/19/2014)... 19, 2014 Merck (NYSE: MRK ), known ... Canada , is teaming with celebrity chef and ... Tus Metas , an educational program encouraging Hispanics with type 2 ... key treatment goal to help reduce the risk of serious health ... at a higher risk for developing type 2 diabetes than non-Hispanic ...
(Date:9/19/2014)... , Sept. 19, 2014 Larry J. ... CVS ), will speak before the National Press Club ... discuss the company,s recent move to stop selling tobacco products ... the future of health. "Dramatic changes in our ... care providers and government," Merlo has said. "CVS Health has ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... 23 DuPont (NYSE: DD ) and ... joint venture to develop, manufacture and commercialize advanced surgical ... venture will be named Actamax Surgical Materials LLC. Under ... share a 50 percent interest. The joint venture ...
... Precision Therapeutics announced today that President and Chief ... Magazine 2010 Pacesetters Award.  The award honors thirteen ... influence in the community-at-large as well as within ... Tuesday, September 21st at the Kean Theatre in ...
Cached Medicine Technology:DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 2DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 3DuPont and DSM Announce Joint Venture in Surgical Biomedical Materials 4Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award 2
Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
Epilation forceps straight ends size 3.5"....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, extra delicate, straight....
Medicine Products: